CRIDANIMOD

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H11NO3
Molecular Weight	253.2527
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CN1C2=C(C=CC=C2)C(=O)C3=C1C=CC=C3

InChI

InChIKey=UOMKBIIXHQIERR-UHFFFAOYSA-N

InChI=1S/C15H11NO3/c17-14(18)9-16-12-7-3-1-5-10(12)15(19)11-6-2-4-8-13(11)16/h1-8H,9H2,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C15H11NO3
Molecular Weight	253.2527
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.xeneticbio.com/news-media/press-releases/detail/38/xenetic-biosciences-announces-fda-acceptance-of
Curator's Comment: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02064725 | https://clinicaltrials.gov/ct2/show/NCT03077698

Cridanimod (Virexxa) is a small-molecule immunomodulator and interferon inducer, which, in preliminary studies, has been shown to increase progesterone receptor expression in endometrial tissue. Restoration of progesterone receptor expression may re-sensitize endometrial tumor tissue to progestin therapy in previously unresponsive tumors. Cridanimod was originally developed by Polysan and Pharmsynthez and licensed to Xenetic Biosciences. Virexxa is currently being studied in an ongoing Phase 2 multi-national study in conjunction with progestin therapy for the treatment of endometrial cancer in women with the recurrent or persistent disease who have failed progestin monotherapy.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
progesterone receptor signaling pathway 2 Target ID: GO:0050847 Sources: https://www.xeneticbio.com/news-media/press-releases/detail/38/xenetic-biosciences-announces-fda-acceptance-of	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Recurrent or persistent endometrial carcinoma 2 Sources: https://clinicaltrials.gov/ct2/show/NCT02064725	Primary		Phase II 1132	Unknown Approved Use Unknown
Endometrial cancer 43 Sources: https://clinicaltrials.gov/ct2/show/NCT03077698	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Increase in NK-activity using superlow doses of the immunomodulator cycloferon].	2001	11552653
Correlations between in vitro effects of preparations of interferon and its inducers on blood cells in patients with multiple sclerosis.	2001 Apr	11550032
[Cycloferon in treating duodenal ulcers in rats].	2001 Nov-Dec	11871237
[Pulmonary surfactant and blood serum in patients with chronic obstructive bronchitis on differentiated therapy].	2002 Apr-Jun	12145894
Regulation of cytokine mRNAs by interferon and interferon inducers.	2002 Jul	12687259
[Treatment of patients with invasive bladder cancer].	2002 Nov-Dec	12577575
[Effect of interferon inductors on infection induced by hepatitis C virus and activity of mRNA cytokines in cell cultures SW-13 and MT-4].	2002 Nov-Dec	12508677
[Neuroimmunopathological mechanisms of preclinical epileptogenesis and their correction by cycloferon].	2003	14763254
Direct antiviral effect of cycloferon (10-carboxymethyl-9-acridanone) against adenovirus type 6 in vitro.	2003 Apr	12742573
[Use of cycloferon in a combined treatment of chlamydial conjunctivitis].	2003 Jan-Feb	12608044
[Cytokinin inducing and antiviral activity of cycloferon on experimental herpetic infection].	2003 Jul-Aug	12966893
[Neuroimmunopathologic aspects of epilepsy].	2004	15455693
[Cycloferon--a new domestic preparation for the prophylaxis of influenza and other acute respiratory viral infections].	2004 Nov-Dec	15636140
[Cyclopheron pretreatment in opisthorchiasis management in patients with viral hepatitis C].	2005	16404860
[Individual changes of gene expression in the interferon system in human blood cells due to amixin and cycloferon].	2005 Mar-Apr	15881395
[Some pathogenic mechanisms of aerozol-therapy including cyclopheron treatment in patients with chronic rhinitis].	2006 May	16783061
[Effect of intranasal aerosol-therapy with cycloferon on the function of respiration in patients with some forms of rhinitis].	2007 Jan	17327631
[Improvement of natural resistance in children for prophylaxis of influenza and acute respiratory tract viral infections (results of multicenter randomized trials)].	2009	20415263
[Cycloferon, as an agent in the therapy and urgent prophylaxis of influenza and acute respiratory tract viral infection (multicentre randomized controlled comparative study)].	2009	20201401
[Type 1 and type 2 interferon inductor (cycloferon) in therapy of children with pyelonephritis associated with herpes viruses].	2009	20052918
[Up-to-date approach to treatment of inflammatory infections in the maxillofacial region].	2009	19711852
[Cycloferon efficacy in viral and bacterial diseases of children (clinical review)].	2010	21574424
[Optimization of prophylaxis of relapses of primary erysipelas with the use of cyclopheron].	2010	21395032
[Use of cycloferon in the treatment of patients with pulmonary tuberculosis with mild clinical manifestations].	2010	21381350
[The cytokine profile in the acute period of tick-borne neuroinfections in children].	2010	21322819
[Clinical laboratory approaches to parodontitis treatment optimization].	2010	21311440
[Effectiveness of cycloferon liniment in a complex treatment, and monitoring of cytokine profile of gingival fluid of patients with paradontitis].	2010	21207889
[Optimization of parodontitis treatment of patients with tuberculosis].	2010	21186645
[Changes of functional activity of peripheral blood leukocytes during the immunotherapy of tick-borne infections in children].	2010	21183923
[Cycloferon in complex therapy of chronic brucellosis].	2010	21140564
[The use of cycloferon in the combined treatment of tuberculosis patients infected with HIV and viral hepatitis].	2010	21089459
[Correction of immunity disorders, treatment of intestinal infections and disbiosis in children (clinical review)].	2010	21033474
[Pathogenetically substantiated therapy of patients with virus hepatitis C, quality of life, and the disease outcome risk (clinical survey)].	2010	20695208
[Efficacy of cycloferon in the treatment of brucellosis].	2010	20608067
[Cycloferon efficacy in the treatment of acute respiratory tract viral infection and influenza during the morbidity outbreak in 2009-2010].	2010	20583555
[Parodontitis immunotropic therapy in patients with chronic viral and bacterial infections].	2010	20559229
[Clinical efficiency of the use of interferon inductors in surgical patients].	2010	20559225
[Improvement of parodontitis therapy of patients with HIV-infection].	2010	20517247
[Use of immunomodulators in the therapy of chronic hepatitis C: improving standard approach].	2010 Apr	20486553
[Combined cycloferon treatment of tuberculosis in patients infected with HIV].	2010 Jul	20821978
[Focal immunophysiotherapy in combined treatment of men with manifestations of papilloma virus infection].	2010 Nov-Dec	21427998

Patents

Sample Use Guides

In Vivo Use Guide

Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).

Route of Administration: Intramuscular

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:18:13 GMT 2023` Edited by `admin` on `Fri Dec 15 16:18:13 GMT 2023`
Record UNII	X91E9EME19
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CRIDANIMOD

Official Name

English

Cridanimod [WHO-DD]

Common Name

English

cridanimod [INN]

Common Name

English

9-OXO-10-ACRIDANACETIC ACID

Systematic Name

English

10-(CARBOXYMETHYL)-9-ACRIDINONE

Systematic Name

English

10(9H)-ACRIDINEACETIC ACID, 9-OXO-

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

L03AX18